Leishmaniasis treatment--a challenge that remains: a review.
Leishmaniasis is a disease caused by flagellate protozoan Leishmania spp. and represents an emergent illness with high morbidity and mortality in the tropics and subtropics. Since the discovery of the first drugs for Leishmaniasis treatment (i.e., pentavalent antimonials), until the current days, the search for substances with antileishmanial activity, without toxic effects, and able to overcome the emergence of drug resistant strains still remains as the current goal. This article reports the development of new chemotherapies through the rational design of new drugs, the use of products derived from microorganisms and plants, and treatments related to immunity as new alternatives for the chemotherapy of leishmaniasis.
Santos
Dilvani O
DO
Laboratório de Biopatógenos e Ativação Celular, Departamento de Biologia Celular e Molecular, Instituto de Biologia, Universidade Federal Fluminense, Av. Barros-Terra s/n Valonguinho, Niterói, Rio de Janeiro CEP 24001-970, Brazil. santosdilvani@gmail.com
Coutinho
Carlos E R
CE
Madeira
Maria F
MF
Bottino
Carolina G
CG
Vieira
Rodrigo T
RT
Nascimento
Samara B
SB
Bernardino
Alice
A
Bourguignon
Saulo C
SC
Corte-Real
Suzana
S
Pinho
Rosa T
RT
Rodrigues
Carlos Rangel
CR
Castro
Helena C
HC
D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D001688:Biological Products / Q000627:therapeutic use; D015195:Drug Design; D006801:Humans; D007896:Leishmaniasis / Q000188:drug therapy*
D000981:Antiprotozoal Agents; D001688:Biological Products